Shire to Relocate Over 500 Jobs to Massachusetts

Shire to Relocate Over 500 Jobs to Massachusetts Establishes Lexington, Mass., as U.S. Operational Headquarters; Decreases Presence in Chesterbrook, Pa. Interim CFO Appointed Lexington,Mass., November19, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) todayannounced plans to relocate over 500 positions to Massachusetts from itsChesterbrook, Pennsylvania, site and establish Lexington, Massachusetts, as thecompany's U.S. operational headquarters. The transition is a continuation ofthe Company's `One Shire' efficiency program and will streamline businessglobally through two principal locations - Massachusetts and Switzerland - withsupport from a limited number of regional and country-based offices around theworld. Simplifying operations in two principal locations will increase efficienciesand Shire expects to realize approximately $25 million in annual savingsbeginning in 2016. This site strategy will also enable greater alignment andexecution of priorities between the Company's commercial and research anddevelopment (R&D) teams to more effectively bring innovative products topatients, as well as strengthen collaboration and cross-development ofemployees. "Chesterbrook, the greater Philadelphia area, and the talent of our employeesbased there have been instrumental to Shire's growth and evolution," saidFlemming Ornskov, M.D., Chief Executive Officer. "We've made the decision toconsolidate our U.S. operations in the Massachusetts area to streamlineoperations and drive further efficiencies in the way we run our business andserve patients. Shire has a great opportunity to combine our Chesterbrook andLexington talent with the leading biotech resources in the Massachusetts area,and we consider ready access to these resources an important element in thefuture growth of our company." Shire plans to move employees in several phases beginning in the first quarterof 2015 and targets completion by the first quarter of 2016. All directlyimpacted employees who do not relocate will be offered severance, outplacementservice and other employee assistance. Interim CFO Appointed As previously announced, James Bowling, Interim Chief Financial Officer (CFO),will be leaving Shire. James' departure date will now be February 28, 2015.Jeff Poulton, Head of Investor Relations, will assume the role of interim CFOeffective January 1, 2015. The CFO position will be based in Lexington. Jeff Poulton joined Shire in 2003 and has held leadership positions in financesupporting the neuroscience, gastrointestinal and rare disease business units.He oversaw the rare diseases business unit operations in North America, LatinAmerica, and Asia Pacific, and most recently led the integration ofViropharma's rare disease products into the Shire portfolio. Prior to joiningShire, Jeff spent time at Cinergy Corp. and PPG Industries in a variety ofcorporate finance and business development roles, in addition to serving fouryears in the U.S. Navy as a commissioned officer. Jeff received a Bachelor ofArts in economics from Duke University, and a Master of Business Administrationin Finance from the Kelly School of Business at Indiana University. For further information please contact: Investor Relations Jeff Poulton [email protected] +1 781 482 0945 Sarah Elton-Farr [email protected] +44 1256 894157 Media Jessica Cotrone [email protected] +1 781 482 9538 Gwen Fisher [email protected] +1 484 595 9836 Brooke Clarke [email protected] +44 7808 908149 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We focus on providing treatments in Neuroscience, Rare Diseases,Gastrointestinal, and Internal Medicine and we are developing treatments forsymptomatic conditions treated by specialist physicians in other targetedtherapeutic areas, such as Ophthalmology. www.shire.com THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACTOF 1995 Statements included herein that are not historical facts are forward-lookingstatements. Such forward-looking statements involve a number of risks anduncertainties and are subject to change at any time. In the event such risks oruncertainties materialize, Shire's results could be materially adverselyaffected. The risks and uncertainties include, but are not limited to, that: * Shire's products may not be a commercial success; * revenues from ADDERALL XR are subject to generic erosion and revenues from INTUNIV will become subject to generic competition starting in December 2014; * the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues, financial condition and results of operations; * Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contract manufacturers to manufacture other products and to provide goods and services. Some of Shire's products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire's products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time; * the development, approval and manufacturing of Shire's products is subject to extensive oversight by various regulatory agencies. Submission of an application for regulatory approval of any of our product candidates, such as our planned submission of a New Drug Application to the FDA for Lifitegrast, may be delayed for any number of reasons and, once submitted, may be subjected to lengthy review and ultimately rejected. Moreover, regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches; * the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely impact Shire's revenues, financial condition or results of operations; * investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines; * adverse outcomes in legal matters and other disputes, including Shire's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations; * Shire faces intense competition for highly qualified personnel from other companies, academic institutions, government entities and other organizations. Shire is undergoing a corporate reorganization and the consequent uncertainty could adversely impact Shire's ability to attract and/or retain the highly skilled personnel needed for Shire to meet its strategic objectives; * failure to achieve Shire's strategic objectives with respect to the acquisition of ViroPharma Incorporated may adversely affect Shire's financial condition and results of operations; and other risks and uncertainties detailed from time to time in Shire's filingswith the Securities and Exchange Commission, including those risks outlined in"Item 1A: Risk Factors" in Shire's Annual Report on Form 10-K for the yearended December 31, 2013. Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com